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Abstract.
Background: Type 2 diabetes (T2D) is a metabolic condition associated with poor clinical and cognitive outcomes including
vascular disease, depressive symptoms, cognitive impairment, and dementia. In the general elderly population, depression has
been consistently identified as a risk factor for cognitive impairment/decline. However, the association between depression
and cognitive function in T2D has been understudied.
Objective: We investigated the association between depression and cognitive function in a large sample of cognitively normal
elderly with T2D.
Methods: In this cross-sectional study, we examined 738 participants, aged 65–88 years old, enrolled in the Israel Diabetes
and Cognitive Decline study. For each cognitive domain (Episodic Memory, Executive Function, Attention/Working Memory, Language/Semantic Categorization) and Overall Cognition, multiple linear regressions assessed its association with
depression (score greater than 5 on the 15-item version of the Geriatric Depression Scale [GDS]), adjusting for age, sex, and
education.
Results: Depression (n = 66, 8.9%) was associated with worse performance on tasks of Executive Function (p = 0.004),
Language/Semantic Categorization (p < 0.001), and Overall Cognition (p < 0.002), but not Episodic Memory (p = 0.643)
or Attention/Working Memory (p = 0.488). Secondary analyses using GDS as a continuous variable did not substantially change the results. Adjusting also for a history of antidepressant medication use slightly weakened the
findings.
Conclusion: Significant associations of depression with several cognitive domains and Overall Cognition even in cognitively
normal elderly with T2D, suggest that depression may have a role in impaired cognitive function in T2D, which may be
attenuated by antidepressants.
Keywords: Cognitive domains, cognitive function, depressive symptoms, diabetes
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INTRODUCTION
In the general elderly population, the association
between neuropsychiatric symptoms (and in particular depressive symptoms) and cognitive impairment/
decline including dementia has been robustly found
[1, 2]. This association has been reported in the
elderly from different ethnic backgrounds [3] and
has been supported by neuropathological findings [4,
5]. However, longitudinal studies have reported an
association that affects only men [6] or those with
higher educational attainment [7]. Other studies have
found that other characteristics, such as age of onset
of depression and prior cognitive impairment [8–10],
can affect the association of depression with cognitive
function.
In the general elderly population, the associations
between depression and cognitive function differ by
cognitive domain (for a review, see [11]), and have
been reported for all domains [12]. Impairment in
specific cognitive domains has also been reported,
with substantial deficits observed in attention and
information processing speed [13]. Differences may
also be evident in populations with specific medical conditions, such as deficits in episodic memory
in recurrent depression and deficits in attention
and executive function in late-onset depression
[14].
Indeed, elderly with type 2 diabetes (T2D)
and depression are at higher risk of cognitive
impairment/decline [15, 16]. However, the literature
reporting on this association is scarce and inconsistent, and little is known about the cognitive domains
that are compromised. In a cross-sectional study of
elderly people with T2D, Brands and colleagues
examined the association of depressive symptoms
with five cognitive domains, but no association was
found using either a cutoff score for depression,
or the total number of symptoms, or using specific
depression domain scores [17]. In contrast to this
cross-sectional study, a longitudinal study found a
significant association of depressive symptoms with
cognitive decline in three cognitive tests representing
psychomotor function, verbal memory, and executive
function [18], which is largely consistent with those
domains affected in the general elderly population
with depression.
Thus, the present study investigated the crosssectional association of depression with cognitive
function in a well-characterized, cognitively normal (Clinical Dementia Rating [CDR] scale = 0 at
the Israel Diabetes and Cognitive Decline [IDCD]

study entry) elderly population with T2D. This study
is aimed at extending findings from the depression
literature in the general elderly population in two
ways: (1) by examining the association of depression with cognitive function in elderly with T2D and
(2) by identifying specific cognitive domains that are
impaired.
METHODS
Participants
The IDCD study design has been previously
described in detail [19], for 897 participants
with baseline data. Briefly, the IDCD recruited
community-dwelling elderly with T2D (65+ years
old) living in central Israel, from approximately
11,000 clients enrolled in the diabetes registry of the
Maccabi Healthcare Services (MHS). The MHS diabetes registry was established in 1998 to facilitate diabetes management and to improve treatment. Any of
the following criteria, primarily based on the American Diabetes Association, were assessed and sufficient for enrollment into the registry: 1) Hemoglobin
A1c Hemoglobin A1c (HbA1c ) >55.7 mmol/mol; 2)
Glucose >11.10 mmol/l on two exams more than
three months apart; 3) purchase of diabetic medication twice within three months supported by
a HbA1c >47.5 mmol/mol or Glucose >6.94 mmol/l
within half a year; 4) diagnosis of type 2 T2D (ICD-9
code [ http://www.icd9data.com/2007/Volume1]) by
a general practitioner, internist, endocrinologist, ophthalmologist, or type 2 T2D advisor, supported by
an HbA1c >47.5 mmol/mol or Glucose >6.94 mmol/l
within half a year. These criteria have been validated by twenty physicians in MHS against their
own practice record [20]. All blood assessments were
performed during fasting. IDCD inclusion criteria
were having T2D; normal cognition at entry; being
free of any neurological (e.g., Parkinson’s disease,
stroke), psychiatric (e.g., schizophrenia), or other diseases (e.g., alcohol or drug abuse) that might affect
cognition; and having an informant.
For the initial IDCD screening, the electronic medical records of potential participants were screened
by the MHS team for diagnosis of dementia, and its
subtypes, and for cholinesterase inhibitors. If any of
these criteria were present in the potential participant’s record, the potential participant was excluded
from the study. Then, MHS personnel asked potential participants, on the phone, whether a doctor had
ever told them that they have a memory problem, or
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if they had ever been treated for a memory problem.
Those who responded positively were excluded from
the study.
Potential participants were assessed by an IDCD
physician experienced in assessment and diagnosis of
dementia, and were administered the CDR scale [21].
The CDR scale assesses the severity of cognitive and
functional impairment in 6 domains (memory, orientation, judgment and problem solving, community
affairs, home and hobbies, and personal care) through
an interview with the participant and an informant. A
score of 0 represents normal cognition (an inclusion
criterion for the IDCD study), 0.5 represents questionable dementia, and scores of 1 through 3 reflect
increasing severity of dementia [21, 22].
Those with a CDR > 0 (reflecting questionable or
higher levels of dementia severity) were excluded
from the IDCD study and referred back to their
primary physician. Potential participants were also
assessed by a neuropsychologist, who administered
the broad neuropsychological battery. For descriptive purposes, global cognitive function was assessed
with the Mini-Mental State Examination (MMSE)
[23]. It assesses various areas of cognitive functions
(orientation, concentration, memory, language, and
visual construction) and is widely used as a cognitive screening instrument for dementia. Depression
was assessed using the Geriatric Depression Scale
(GDS).
IDCD eligibility was determined by a diagnostic consensus conference that included neurologists,
psychiatrists, and neuropsychologists experienced
with dementia, with at least two specialties present.
It is important to note that the neuropsychological
battery was not used in the process of screening for
normal cognition since it was used to calculate the
cognitive outcome measures.
This study employed prospective historical
diabetes-related data from the MHS, and baseline
cognitive and depression data collected by the IDCD
study on 897 participants. The sample for this
study consisted of the 738 IDCD participants with
complete data on cognitive domains, demographic
characteristics (age, sex, and education), T2D-related
characteristics (HbA1c; number of follow-up years
in the registry, a surrogate for duration of disease
[24]; and whether medication for T2D was taken [no
medication, hypoglycemic medication, and insulin or
insulin + hypoglycemic medication]), and cardiovascular risk factors (body mass index, creatinine, total
cholesterol, triglycerides, and diastolic and systolic
blood pressure).
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Study procedures and informed consent were
approved by the Icahn School of Medicine at Mount
Sinai, Sheba Medical Center, and MHS IRB committees. All participants signed an informed consent.
Predicted cognitive function/outcomes
For the IDCD study (n = 897), cognitive function
at entry was assessed using 13 neuropsychological
tests, grouped into cognitive domains according to
the factor with the highest loading: (1) Episodic
Memory: Word List Memory, Word List Recall,
and Word List Recognition from the Consortium
to Establish a Registry for Alzheimer’s Disease
(CERAD) neuropsychological battery [25, 26]; (2)
Attention/Working Memory: Digit Span (forward
and backward) from the Wechsler Memory ScaleRevised (WMS-R) [27]; (3) Language/Semantic
Categorization: Similarities from the Wechsler Adult
Intelligence Scale-Revised (WAIS-R) [28], Letter
Fluency [29], and Animal Fluency [30]; and (4) Executive Function: Trail Making Test (A and B) [31],
CERAD-Constructional Praxis, Shape Cancellation,
and Digit Symbol from the WAIS-R [28]. Raw scores
were converted to z scores using participants’ means
and SDs. A composite measure of global cognitive
function (Overall Cognition) was created by averaging all the z scores. Scores for the four cognitive
domains were calculated as averages of z scores.
Depression predictor
Depression was the predictor variable, which was
assessed by the 15-item version of the GDS [32].
The GDS is a widely used screening instrument
for depressive symptoms in the elderly population,
which follows a yes/no answer format. The cut-off
score greater than 5, suggesting clinical depression,
was used to define depression as a dichotomous
status [33].
Statistical analyses
The association of depression with each cognitive
outcome was examined using multiple regression
analyses, with Episodic Memory, Attention/Working
Memory,
Language/Semantic
Categorization,
Executive Function, and Overall Cognition as the
dependent variables. The primary analyses, Model 1,
adjusted for the demographic characteristics of age,
sex, and education. In secondary analyses, Model
2, we also adjusted for T2D-related characteristics
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and cardiovascular risk factors, which are potential
confounders that may be associated with cognitive
function [34]. The association of depression with
each cognitive outcome was also examined using
the predictor as a continuous variable (GDS-15 total
score).
We had information from the MHS that some
participants (n = 192) received antidepressant medications at some time point since they entered the
Diabetes Registry, suggesting they had depression.
Thus, the main analyses were repeated adjusting
also for antidepressants. In additional analyses, we
applied multivariate analyses of covariance (MANCOVA) separately in those who had or had not taken
any antidepressant to test the effects of depression status (non-depression versus depression) on cognitive
functioning (the four cognitive domains and Overall
Cognition), adjusting for demographics.
For each of the models of Tables 3 and 4, results for
the five cognitive outcomes were considered “significant” if they met criteria of the Holm multiple comparisons procedure [35], an enhancement of the Bonferroni inequality, at the 0.05 level of significance.

For comparisons of two groups, the small (0.20),
medium (0.50), and large (0.80) conventions for
effect sizes of t-tests are widely used, while the effect
sizes and conventions for the F-test are not. Therefore,
t-test effect sizes are presented for F-tests comparing
two groups. Effect size conventions for Pearson’s chisquare are similarly not familiar. For a 2 × 2 table, the
square root of Pearson’s chi-square is the z-test for
the difference between two proportions, analogous
to the t-test for the difference between means. The
corresponding effect size for the difference between
proportions has the same small, medium, and large
conventions as the t-test.
RESULTS
For the entire sample (n = 738), 66 (8.9%) were
depressed and 672 (91.1%) were not depressed.
Mean age was 71.9 (SD = 4.7). There were more
men (60.3%) than women. The MMSE mean score
was 28.1 (SD = 1.7), which is consistent with normal cognition. Table 1 presents the demographic,
clinical, and cognitive characteristics of the sample

Table 1
Mean ± SD of demographic and clinical characteristics of the participants by their clinical status, non-depression versus depression
N
Age
Education
Male (%)
Female (%)
# of follow up years in the registry
Body mass index (kg/m2 )
Creatinine (mg/dL)
Total cholesterol (mg/dL)
Triglycerides (mg/dL)
Diastolic BP (mmHg)
Systolic PB (mmHg)
Hemoglobin A1c (%), (mmol/mol)
Type 2 diabetes medication (%)
1- No medication (n = 93)
2- Hypoglycemic medication (n = 577)
3-d Insulin or insulin + hypoglycemic medication (n = 68)
GDS-15
Antidepressant use (n = 715) (%)
Antidepressant use at any time point in the diabetes registry (n = 192)
MMSE score (n = 65 for depression)
Attention/Working Memory (SEM)
Executive Function (SEM)
Language/Semantic Categorization (SEM)
Episodic Memory (SEM)
Overall Cognition (SEM)

Non-Depression
672

Depression
66

p
–

Effect Size

72.7 ± 4.6
13.4 ± 3.5
62.8
37.2
10.4 ± 1.5
28.3 ± 4.5
1.0 ± 0.3
180.3 ± 25.2
157.2 ± 65.0
76.7 ± 4.9
134.8 ± 9.5
6.8 (0.8), (51)

73.1 ± 5.0
11.6 ± 2.3
34.8
65.2
10.4 ± 1.2
28.8 ± 4.8
0.9 ± 0.3
183.7 ± 23.8
167.3 ± 62.4
76.4 ± 4.4
135.1 ± 8.8
6.9 (0.8), (52)

0.50a
<0.001a
<0.001b

0.09
0.51
0.57

0.81a
0.43a
0.07a
0.29a
0.22a
0.62a
0.87a
0.24a

0.03
0.09
0.23
0.14
0.16
0.06
0.02
0.15

13.1
78.4
8.5
1.2 ± 1.3

7.6
75.8
16.7
7.5 ± 1.7

0.053b

0.09

<0.001a

4.63
0.45

25.1
28.2 ± 1.6
0.051 (0.064)
0.224 (0.120)
0.250 (0.080)
0.139 (0.080)
0.500 (0.187)

45.9
27.2 ± 2.2
–0.051 (0.208)
–0.956 (0.389)
–0.787 (0.260)
–0.309 (0.261)
–1.480 (0.609)

<0.001b
<0.001a
0.643c
0.004c
<0.001c
0.103c
0.002c

0.58
0.06
0.37
0.49
0.21
0.40

BP, blood pressure; GDS, Geriatric Depression Scale; MMSE, Mini-Mental State Examination; SEM, Standard Error of the Mean. a p-value
by Student’s t-test, b Pearson’s chi-square for percentages, 2 categories. c Analysis of covariance controlling for age, sex, and education. d Since
63 participants received both hypoglycemic and insulin medication and 5 received only insulin, they were combined. Pearson’s chi-square
for percentages, effect size, 10 small, 30 medium, 0.50 large.
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Table 2
Correlations among five cognitive outcomes and cognitive tests
Cognitive Outcomes

n

Episodic
Memory

Executive
Function

Language/
Semantic
Categorization

Attention/
Working
Memory

Overall
Cognition

0.487
0.558
––
0.344
0.804

––
0.466
0.487
0.234
0.687

0.657
0.844
0.804
0.588
––

Correlations
Attention/ Working Memory
Executive Function
Language/Semantic Categorization
Episodic Memory
Overall Cognition

738
738
738
738
738

0.234
0.259
0.344
––
0.588

0.466
––
0.558
0.259
0.844

Cognitive Tests
Attention/Working
Memory
Digit Span
Forward
Digit Span
Backward
Executive Function
Trails A
Trails B
Praxis
Digit Symbol
Shape Cancellation
Language/ Semantic
Categorization
Letter Fluency
Animal Fluency
Similarities
Episodic Memory
Word List Memory
Word List Recall
Word List Recognition

738

0.156

0.350

0.417

0.877

0.576

738

0.253

0.467

0.437

0.879

0.643

737
712
734
737
700

0.202
0.252
0.132
0.264
0.99

0.801
0.811
0.608
0.811
0.648

0.435
0.481
0.359
0.544
0.230

0.331
0.484
0.257
0.435
0.202

0.661
0.739
0.506
0.744
0.461

731
738
737

0.259
0.293
0.274

0.446
0.409
0.486

0.855
0.794
0.754

0.441
0.331
0.398

0.668
0.616
0.650

738
738
738

0.815
0.815
0.635

0.815
0.200
0.101

0.284
0.235
0.127

0.414
0.109
0.113

0.305
0.440
0.307

**p < 0.001.

by depression status (i.e., non-depression versus
depression groups). The depression group had,
on average, fewer years of education (p < 0.001),
lower MMSE scores (p < 0.01), by definition had
higher depression scores, and were more likely
to have taken antidepressants (p < 0.001) than the
non-depression group. The depression group had a
majority of women, while the non-depression group
had a majority of men (p < 0.001). With the exception of Attention/Working Memory (p = 0.643), the
depression group performed more poorly on all cognitive domains (p ≤ 0.019) and Overall Cognition
(p = 0.002) than the non-depression group.
For the 738 participants in this study, Table 2
shows the intercorrelations among the four cognitive
domains and Overall Cognition, and their correlations
with the 13 neuropsychological tests.
Table 3 presents multiple regression results:
the primary analyses adjusting for demographics
(Model 1), and the secondary analyses adjusting
for T2D-related characteristics and cardiovascular
risk factors (Model 2). Model 1 analyses showed

significant associations of depression with poorer
cognitive performance in the Executive Function
domain (partial r = –0.106, t = –2.893, p = 0.004),
Language/Semantic Categorization domain (partial r = –0.139, t = –3.79, p < 0.001), and Overall
Cognition (partial r = –0.114, t = –3.096, p = 0.002).
Although strongly significant, these associations
(individually) explained ≤0.019 of the variability
in cognitive performance. These results remained
largely unchanged using Model 2.
We repeated the Model 1 analyses by examining depression as a continuous variable (GDS-15
total score) and adjusting for demographics. Results
remained significant, with a slight increase in effect
size, for the same three cognitive outcomes, Executive Function, Language/Semantic Categorization,
and Overall Cognition (partial r ≤ –0.175, t ≤ –4.818,
p < 0.001), and one additional domain, Episodic
Memory, became significant (partial r = –0.093,
t = –2.538, p = 0.011). These results remained largely
unchanged using Model 2. Of note, since GDS-15
total score was not normally distributed, when the
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Table 3
Associations of depression, as assessed by the dichotomized GDS-15, with performance on cognitive domains
and overall cognition
Partial ra

␤ (95% CI)

p

Partial rb

␤ (95% CI)

p

Attention/Working
Memory
Executive Function

–0.017

0.643

–0.016

0.004c

–0.103

–0.139

<0.001c

–0.138

–0.060

0.103

–0.058

Overall Cognition

–0.114

0.002c

–0.112

–0.094
(–0.525, 0.336)
–1.123
(–1.918, –0.329)
–1.025
(–1.562, –0.487)
–0.431
(–0.973, 0.111)
–1.954
(–3.216, –0.692)

0.668

Language/Semantic
Categorization
Episodic Memory

–0.102
(–0.531, 0.328)
–1.180
(–1.981, –0.379)
–1.037
(–1.573, 0.500)
–0.448
(–0.987, 0.090)
–1.980
(–3.235, –0.724)

–0.106

0.006c
<0.001c
0.119
0.002c

T2D, type 2 diabetes; HbA1c, hemoglobin A1c; BMI, body mass index; BP, blood pressure; ␤, Average difference
in cognitive performance (dependent variable) of participants with depression compared to those without depression.
a Adjusting for demographics (age, sex, and education). b Adjusting for demographics, T2D-related characteristics (HbA1c,
number of follow up years in the registry, and type 2 diabetes medication), and cardiovascular risk factors (BMI, creatinine,
total cholesterol, triglycerides, and diastolic and systolic BP). c Significant at 0.05 level by Holm multiple comparisons
procedure.
Table 4
Means and standard error of the mean (SEM) of Z scores of cognitive performance by antidepressant use and depression status
Cognitive domain
n
Attention/Working
Memory
Executive Function
Language/Semantic
Categorization
Episodic Memory
Overall Cognition

Nondepression

Non-Antidepressant
Depression
F
(df = 1, 518)

p

Effect
Size

Nondepression

Antidepressant
Depression
F
(df = 1, 187)

p

Effect
Size

490
33
0.145 (0.075) 0.014 (0.296)

0.184

164
28
0.668 0.08 –0.170 (0.127) 0.099 (0.312)

0.632

0.428 0.16

0.496 (0.139) –0.686 (0.544)
0.382 (0.092) –0.630 (0.361)

4.415
7.335

0.036 0.38 –0.429 (0.245) –0.880 (0.600)
0.007a 0.49 –0.006 (0.169) –0.604 (0.412)

0.478
1.785

0.490 0.14
0.183 0.27

0.193 (0.089) 0.324 (0.348)
0.840 (0.212) –0.795 0.830)

0.134
3.627

0.715 0.07 0.058 (0.176) –0.339 (0.430)
0.057 0.34 –0.184 (0.395) –0.865 (0.967)

0.724
0.422

0.396 0.17
0.517 0.13

Note: Adjusting for age, sex, and education. Effect size is for t-test comparing two groups. a Significant at 0.05 level by Holm multiple
comparisons procedure.

Model 1 analyses were repeated using logarithmic
transformation (which reduced kurtosis to –0.8 from
its original value of 3.6), findings remained largely
consistent, but Episodic Memory was no longer significant (p = 0.062).
In the subsample of 715 participants with
antidepressant use information, the results for
the association of depression with poorer Executive Function (p = 0.026) and Overall Cognition
(p = 0.040) lost significance by the Holm criterion,
but the Language/Semantic Categorization domain
(p = 0.002) remained significant. The MANCOVA
in this subsample showed that among the 26.9%
(n = 192) who had taken any antidepressant, cognitive
functioning was similar in the depressed and nondepressed groups (Table 4). The latter result remained
non-significant when cognitive outcomes were
compared by antidepressant classes (i.e., SelectiveSerotonin Reuptake Inhibitors [SSRIs], Serotonin-

Norepinephrine Reuptake Inhibitors [SNRIs], and
tricyclics). However, due to the small sample size,
the antidepressant class result should be interpreted
with caution since the largest comparison consisted
of those who were taking SSRIs (n = 36) versus those
who were not (n = 30). In contrast, among those
who had not taken antidepressants, test performance
was significantly worse in the depressed subgroup
in the Language/Semantic Categorization (p = 0.007)
domain, as compared to the non-depressed group
(Table 4).
DISCUSSION
This study investigated the association of depression with performance on four different cognitive
domains and on Overall Cognition in participants
with T2D. Depression was associated with poorer
cognitive performance on Executive Function and
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Language/Semantic Categorization, and with poorer
Overall Cognition, but not on Episodic Memory
or Attention/Working Memory, after adjusting for
demographics (age, sex, and education). With the
exception of Episodic Memory, which was not significant, these results are largely consistent with those
on the association between depression and cognition in the general elderly population. The Episodic
Memory result suggests that impaired memory may
be less frequently observed in the depressed diabetic population as compared to the depressed general
elderly population. T2D is associated with vascular
risks and diseases, which in turn are associated with
impairment in information processing speed. Most of
the tasks in the Language/Semantic Categorization
and the Executive Function domains were timed, for
which good performance relied heavily on how fast
participants processed the information on which they
were being tested.
Depression explained ≤1.9% of the variability in
each cognitive domain and in Overall Cognition.
These results remained largely unchanged after further adjusting for T2D-associated characteristics and
cardiovascular risk factors. Although, this might be
a result of the relatively small prevalence (8.9%, as
assessed by the GDS) of depression in this sample,
the associations were less significant when antidepressant use (which yielded a higher rate: 26.9%,
n = 715) was used as the predictor of cognition. It is
noteworthy that the 8.9% prevalence is similar to that
reported in non-T2D population-based studies [36],
but smaller than that reported in T2D studies [37].
This discrepancy can be at least partially explained by
the inclusion of a population-based sample as compared to a clinical sample, the eligibility criteria of
the study, which required normal cognition, and the
depression screening method. It is also possible that
the potential effects of T2D on cognitive function
masked the association of depression with cognitive
function. This latter possibility is not the case in studies of depression in the general elderly population
since these older adults may or may not have T2D.
The lack of report of the effect sizes of the association make comparisons of these results with those
of other studies challenging. One cross-sectional
study with a small sample (n = 52 white non-diabetic
older adults) reported larger effect sizes (correlations
ranging from 0.311 to 0.497) for the associations
between depressive symptoms (as measured by the
total score or two individual items from the Hamilton
Depression Rating Scale) [38] and cognitive status,
after controlling for demographics [3].
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However, our results are in line with studies that
included a T2D population and found either no association or small effects. For example, Brands and
colleagues failed to find an association of cognitive performance with the cut-off score, the total
score, or subdomain scores from the Beck Depression
Inventory [17]. The longitudinal study by Sullivan
and colleagues with a sample size of over 2,700
participants reported a link between depression and
cognitive decline, with results remaining significant after adjusting for important confounders such
as demographics, lipid treatment, and cardiovascular disease, and when the depression instrument
was used as a continuous variable [18]. Although,
Sullivan et al. addressed a different question from
ours on the role of depression in cognition, their
reported effect sizes were also small. The discrepancy in research findings across different studies
may reflect, at least partially, differences in research
design/methodology (e.g., longitudinal versus crosssectional design, sample size and characteristics of
participants, instruments used to assess depression
and cognitive performance, and operational definition
of depression: cutoff score, total depression score,
or clinical diagnosis based on established diagnostic
criteria). Results for the dichotomized GDS-15 and
total score were largely similar. The IDCD sample
is by eligibility criteria cognitively normal at baseline. Although within normal cognition the sample
showed substantial variability in cognitive performance, it is possible that exclusion of cognitively
impaired individuals explains the small association of
depression with cognition in this sample. Consistent
with this argument, elderly who were hospitalized
for major depression and had symptoms of dementia
that subsided after treatment for depression had a 4.7times higher risk of developing frank dementia after
a period of 3 years compared to hospitalized patients
whose depression was not accompanied by dementia
symptoms [9].
Psychological distress like depression can be an
emotional reaction to a chronic medical condition
such as T2D and may have different biological etiologies. In the elderly, depression that is associated
with cerebrovascular disease has been referred to as
“vascular depression.” [39]. This concept has also
been supported by the presence of microbleeds in
late-onset depression as compared to early onset
depression [40]. The small effect size of the association between depression and cognition in T2D is
surprising in view of the strong link between vascular disease and T2D (for a review, see [41]). Indeed,
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our results showed that participants with depression were not more likely to present with vascular
risks (body mass index, total cholesterol, triglycerides, and diastolic and systolic blood pressure) than
those without. This is consistent with Brands and colleagues’ findings showing that depression was neither
linked to hypertension, nor to micro- or macrovascular events, nor to white matter abnormalities
[17]. Overall, these findings suggest that mechanisms
underlying depression in T2D might originate from
neurobiological substrates other than cerebrovascular
risks/diseases [42–45], or be linked to cerebrovascular disease [46] such as brain atrophy, interleukins,
and cortisol levels. In the general elderly population
with major depressive disorder, Smagula and colleagues reported significant findings from pilot data
on the associations among immunological markers,
brain structure, and executive function [47]. Similarly, Charlton and colleagues reported an association
between pro-inflammatory cytokines and memory
function in late-life depression [48].
Within the depression group, relatively more participants took some diabetes medication and received
more intensive treatment including insulin, which
may suggest that depressed elderly with diabetes
are at heightened risk of worse disease or poor
diabetes management (due to difficulty following a
diet or medication adherence), and of poorer cognitive performance before receiving intensive T2D
treatment.
Because depression is strongly associated with
psychomotor retardation [49], we reorganized the
neuropsychological tests into composites of timed
and untimed tests (data not shown). Partial correlations with depression showed that the depression
group tended to perform worse on both types of
tests (partial r controlling for demographics: timed,
r = –0.073, p = 0.06; untimed, r = –0.100, p = 0.007),
but the effects were small.
An area of research that remains largely unresolved in the general and T2D populations, is the
effect of antidepressant medication on cognition. In
the general elderly population, at least two classes
of antidepressants, the SNRIs (specifically duloxetine) and the atypical antidepressants (specifically
vortioxetine), have been reported to improve cognitive function, in particular memory and executive
function [50, 51]. However, another class of antidepressant, the SSRIs (specifically citalopram), has
been reported to decrease overall cognitive function
in patients with AD [52]. Similarly, another study
found MMSE scores declined after treatment with

SSRIs for depression or Obsessive-Compulsive Disorder [53]. In this study, we examined associations
of antidepressant classes with cognitive functioning
in participants who had taken antidepressants at any
time point since entering the MHS diabetes registry
(n = 192). Our results showed that there were no significant differences in cognitive functioning between
depressed and non-depressed participants who were
on antidepressants of any class, or in those who were
on a specific antidepressant class. However, the latter
has to be interpreted with caution due to the small
sample size of the subgroups.
This study had several limitations including
the cross-sectional design, so causation cannot be
inferred. The study lacked a non-T2D control group
that would permit examining whether the associations found and their strengths are generalizable to
non-T2D elderly. Similarly, this study excluded cognitively impaired T2D participants (such as those
with mild cognitive impairment), thus preventing
examination of the association in those who are at
heightened risk of dementia. The use of follow up
years in the diabetes registry as a surrogate for duration of T2D was a truncated estimate for all those who
already had T2D when entering the registry, so the
reported values are underestimates. Neuroimaging
data that were not available could have helped explore
the biological basis of depression and of diminished
cognition in this sample (e.g., white matter hyperintensities and silent brain infarcts). To the extent that
cerebrovascular disease may be a biological mechanism linking the association between depression and
poorer cognition in T2D, excluding participants with
stroke (an eligibility criterion of the IDCD study)
could have diminished the magnitude of the associations. This study did not include as predictors age of
depression onset or duration since then. Recent longitudinal studies finding age or duration modulation of
dementia risk associated with depression suggest that
depression may be an early sign of dementia, a condition that shares a common cause, or even dementia
that was misdiagnosed [10, 54–56].
Strengths of this study included a large sample size, a well-characterized diagnosis of T2D,
well-defined and numerous measurements of T2D
characteristics, and a comprehensive neuropsychological battery. This battery permitted the evaluation
of Overall Cognition and specific cognitive domains.
Availability of antidepressant treatment information
through the MHS registry permitted exploration of
its contribution to the relationship of depression with
cognition.
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In summary, these results showed a significant
but small association between depression and cognitive function; depression and impaired cognition
may have common but also other distinct underlying
neurobiological mechanisms. Investigation of these
mechanisms may be an important goal for future
research that includes T2D and non-T2D elderly.

[10]

[11]

[12]

ACKNOWLEDGMENTS
This study was supported by NIA grants R01
AG034087 to Dr. Beeri and P50 AG05138 to
Dr. Sano, the Helen Bader Foundation and the
Leroy Schecter Foundation to Dr. Beeri, and the
Alzheimer’s Association grant MNIRGD-14-321113
to Dr. Guerrero-Berroa.
Authors’ disclosures are available online (https://
www.j-alz.com/manuscript-disclosures/17-0778r2).

[13]

[14]

[15]

REFERENCES
[16]
[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT,
Schneider JS, Bach J, Pilat J, Beckett LA, Arnold SE, Evans
DA, Bennett DA (2002) Depressive symptoms, cognitive
decline, and risk of AD in older persons. Neurology 59,
364-370.
Ismail Z, Malick A, Smith EE, Schweizer T, Fischer C
(2014) Depression versus dementia: Is this construct still
relevant? Neurodegener Dis Manag 4, 119-126.
Guerrero-Berroa E, Kluger A, Schmeidler J, Sailor K,
Lizardi H, Golomb J, Ferris S, Reisberg B (2014) Neuropsychological and neuropsychiatric prediction of global
cognitive status among older Spanish-speaking Hispanics
and English-speaking whites. J Geriatr Psychiatry Neurol
27, 266-275.
Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M,
Perl DP, Purohit DP, Gorman JM, Haroutunian V (2006)
Increased hippocampal plaques and tangles in patients with
Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 63, 161-167.
Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP,
Haroutunian V, Sano M (2008) Increased neurofibrillary
tangles in patients with Alzheimer disease with comorbid
depression. Am J Geriatr Psychiatry 16, 168-174.
Cervilla JA, Prince M, Joels S, Mann A (2000) Does depression predict cognitive outcome 9 to 12 years later? Evidence
from a prospective study of elderly hypertensives. Psychol
Med 30, 1017-1023.
Geerlings MI, Schmand B, Braam AW, Jonker C, Bouter
LM, van Tilburg W (2000) Depressive symptoms and risk of
Alzheimer’s disease in more highly educated older people.
J Am Geriatr Soc 48, 1092-1097.
van Reekum R, Simard M, Clarke D, Binns MA, Conn D
(1999) Late-life depression as a possible predictor of dementia: Cross-sectional and short-term follow-up results. Am J
Geriatr Psychiatry 7, 151-159.
Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma
T (1993) The course of geriatric depression with “reversible

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

691

dementia”: A controlled study. Am J Psychiatry 150, 16931699.
Singh-Manoux A, Dugravot A, Fournier A, Abell J, Ebmeier
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